Unlock instant, AI-driven research and patent intelligence for your innovation.

Cancer therapy

A cancer and mycobacterial technology, applied in antibody medical ingredients, bacterial medical raw materials, drug combinations, etc., can solve the problems of worsening inflammatory response and side effects

Inactive Publication Date: 2016-03-16
IMMODULON THERAPEUTICS
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Prior art combination therapy can thus worsen the inflammatory response and have serious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0107] This example describes the study of heat-killed, whole-cell Mycobacterium albicans (IMM-101) and the mTor inhibitor rapamycin (West. Romos). Genetically engineered mice carrying mutations in Kras and Pdx-Cre (KC mice) were bred according to the method described by Hingorani et al. (Cancer Cell, 2003, 4:437-50); Ductal lesions of intraepithelial neoplasia that can progress to invasive and metastatic adenocarcinoma. Using 10 mutants in Kras, p53 and Pdx-Cre 5 KC mice were orthotopically injected with KPC cells (Hingorani et al., Cancer Cell, 2005, 7:469-48) at postnatal day 100. On day 114 ( figure 1 Day 0 in ) mice were treated as follows:

[0108] - 12 mice were untreated (control);

[0109] - 12 mice were treated with 2 mg / kg rapamycin intraperitoneally daily for the entire length of the study;

[0110]- 12 mice were treated with 0.1 mg IMM-101 / mouse, alternately injected subcutaneously in the nape of the neck and at the base of the tail on alternate days during ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention resides in the preparation of a medicament to aid in the treatment of cancer. According to the invention there is a whole cell Mycobacterium for use in the treatment of neoplastic disease in combination with an mTOR inhibitor, wherein the Mycobacterium is a non-pathogenic heat-killed Mycobacterium.

Description

field of invention [0001] The present invention relates to the field of cancer therapy. In particular, the invention relates to methods of preventing, treating or inhibiting the development of tumors or metastases in a subject in combination with an mTOR inhibitor and to immunomodulators useful in such therapy. Background technique [0002] In recent years, there has been growing awareness of the important role of the immune response in cancer biology, clearing many tumors very early and maintaining those tumors that avoid complete clearance in a state of equilibrium, sometimes for years (Dunn et al., AnnuRevImmunol 2004 ; 22:329-360). Eventual escape from this equilibrium phase with clinical disease manifestations is associated with a dysregulation of the immune response, manifested, for example, by chronic inflammation or immunosuppression. Strong and growing evidence of the critical role of the immune system in the development, structural properties and progression of c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K31/436A61P35/00
CPCA61K35/74A61K31/436A61P35/00A61P35/02A61P43/00A61K39/04A61K45/06A61K2039/521A61K2039/54A61K2039/542A61K2039/544A61K2039/585
Inventor T·哈格曼
Owner IMMODULON THERAPEUTICS